Soligenix announces promising results in extended HyBryte treatment study for cutaneous T-cell lymphoma
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, has shared an interim update on a key study involving extended HyBryte treatment in patients with early-stage ... Read More